An Open-label, Non-randomized, 52-Week Study to Evaluate Treatment Holidays and Rebound Phenomenon After Treatment With Belimumab 10 mg/kg in Systemic Lupus Erythematosus Subjects
Phase of Trial: Phase III
Latest Information Update: 14 Jan 2019
Price : $35 *
At a glance
- Drugs Belimumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 08 Jan 2019 Status changed from active, no longer recruiting to completed.
- 18 Sep 2017 Planned End Date changed from 23 Aug 2019 to 13 Dec 2018.
- 18 Sep 2017 Planned primary completion date changed from 14 Dec 2018 to 13 Dec 2018.